title: Relationship between baseline blood pressure parameters (including mean pressure, pulse pressure, and variability) and early outcome after stroke: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
abstract: OBJECTIVE
  High blood pressure (BP) in acute stroke is associated independently with a poor outcome. Recent evidence suggests that other hemodynamic parameters may also be associated with outcomes following stroke.
  
  
  METHODS
  The relationship between baseline BP, heart rate, and other hemodynamic parameters, and early outcomes were assessed using data from TAIST trial.
  
  
  RESULTS
  Death or neurological deterioration at day 10 was associated, both in unadjusted and adjusted analyses, with systolic BP (adjusted OR, 1.02; 95% CI, 1.01-1.03), mean arterial pressure (OR, 1.02; 95% CI, 1.01-1.04), pulse pressure (OR, 1.02; 95% CI, 1.01-1.03), and BP variability (OR, 1.03; 95% CI, 1.01-1.05). Similar relationships were noted for deterioration alone, and recurrent stroke.
  
  
  CONCLUSIONS
  Early death or neurologic deterioration, deterioration, and recurrent stroke are associated independently with high systolic BP, mean arterial pressure, pulse pressure, and BP variability. These measures offer potential therapeutic targets for improving early outcome after acute ischemic stroke.
authors.affiliation: Division of Stroke, University of Nottingham, City Hospital Campus, Nottingham NG5 1PB, UK.
authors.forename: Chamila
authors.initials: C
authors.lastname: Geeganage
authors.forename: Michael
authors.initials: M
authors.lastname: Tracy
authors.forename: Timothy
authors.initials: T
authors.lastname: England
authors.forename: Gillian
authors.initials: G
authors.lastname: Sare
authors.forename: Thierry
authors.initials: T
authors.lastname: Moulin
authors.forename: France
authors.initials: F
authors.lastname: Woimant
authors.forename: Hanne
authors.initials: H
authors.lastname: Christensen
authors.forename: Peter Paul
authors.initials: PP
authors.lastname: De Deyn
authors.forename: Didier
authors.initials: D
authors.lastname: Leys
authors.forename: Desmond
authors.initials: D
authors.lastname: O'Neill
authors.forename: E Bernd
authors.initials: EB
authors.lastname: Ringelstein
authors.forename: Philip M W
authors.initials: PM
authors.lastname: Bath
mesh_terms: D000368:Aged; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D012008:Recurrence; D020521:Stroke / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology*; D013997:Time Factors; D000078222:Tinzaparin; D016896:Treatment Outcome
chemical_list: D006495:Heparin, Low-Molecular-Weight; D000078222:Tinzaparin